antiPD1 (N=17)	Bispecific (N=7)	P-value
Gender
Female	5 (29.4%)	2 (28.6%)	1
Male	12 (70.6%)	5 (71.4%)
Age (years)
Mean (SD)	67.2 (8.79)	57.0 (11.2)	0.397
Median [Min, Max]	68.0 [49.0, 81.0]	63.0 [35.0, 65.0]
Objective response
PD	3 (17.6%)	3 (42.9%)	0.191
PR	9 (52.9%)	1 (14.3%)
SD	5 (29.4%)	3 (42.9%)
Pathological stage
II	0 (0%)	1 (14.3%)	0.16
III	3 (17.6%)	0 (0%)
IV	14 (82.4%)	6 (85.7%)
PFS
Mean (SD)	11.0 (6.46)	6.70 (4.84)	0.424
Median [Min, Max]	10.7 [2.80, 23.8]	5.10 [2.10, 15.5]
PFS status
0	5 (29.4%)	0 (0%)	0.289
1	12 (70.6%)	7 (100%)
OS
Mean (SD)	32.7 (15.2)	33.9 (33.1)	0.404
Median [Min, Max]	27.4 [12.2, 62.1]	16.6 [10.7, 96.7]
OS status
0	10 (58.8%)	6 (85.7%)	0.427
1	7 (41.2%)	1 (14.3%)
Clinical benefit
DCB	13 (76.5%)	2 (28.6%)	0.082
NDB	4 (23.5%)	5 (71.4%)